COMPARATIVE PHARMACODYNAMIC CHARACTERISTICS OF IVABRADINE IN PATIENTS WITH CORONARY ARTERY DISEASE: STABLE ANGINA PECTORIS
##plugins.themes.academic_pro.article.sidebar##
Downloads
##plugins.themes.academic_pro.article.main##
Abstract
The development of recommendations based on the results of clinical trials with a unified approach to treatment, modern drugs for the treatment of coronary artery disease, undoubtedly, led to a significant improvement in the quality of life of patients and prognosis, at the same time, the disease is still prognostically unfavorable. improving the quality of life and prognosis, slowing down the progression of the disease became possible due to the creation of a new drug, an inhibitor of If-channels, ivabradine. The effective effect of ivabradine on the incidence of outcomes (death or hospitalization for coronary artery disease) was manifested in patients of different sex and age in the early stages of treatment and was maintained throughout the observation period.
##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2018: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). // Eur. Heart J. – 2018. – Vol. 29, N 19. – P. 2388–2442.
- Диагностика и лечение хронической сердечной недостаточности. Национальные клинические рекомендации. Сб. / Под ред. Р.Г. Оганова. – 3-еизд. – М., 2016. – C. 67–160.
- The European health report 2019: health and health systems 2017 // www.euro.who.int
- Cleland J.G., Swedberg K., Follath F. et al. // Eur. Heart J. – 2014. – Vol. 24, N 5. – P. 442–463.
- Fox K., Borer J.S., Camm J. et al. // J. Amer. Coll. Cardiol. – 2017. – Vol. 50. – P. 823–830.
- Fox K., Garcia M.A., Ardissino D. et al. // Eur. Heart J. – 2016. – Vol. 27. – P. 1241–1381.
- Mulder P., Barbier S., Chagraoui A. et al. // Circulation. – 2014. – Vol. 109. – P. 1674–1679.
- Fox K., Ferrari R., Tendera M. et al. // Am. Heart J. – 2016. – Vol. 152, N 5. – P. 860–866.
- Tardif C., Berry C. // Eur. Heart J. – 2006. – Vol. 8 (suppl. D). – D24–D29.
- Steg P.G. // Medicographia. – 2019. – Vol. 4, N 31. – P. 371–376.
- Drouin A, Gendron M.E., Thorin E. et al. // Br. J. Pharmacol. – 2018. – Vol. 154, N 4. – P. 749–757.
- Ferrari R., Nesta F., Boraso A. // Eur. Heart J. – 2011. – Vol. 1. – H24–H28.